{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:35:50Z","timestamp":1785803750103,"version":"3.56.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hypophosphatasia is a rare bone disease characterized by impaired bone mineralization and low alkaline phosphatase activity. Here, we describe the course of bone-targeted enzyme replacement therapy with asfotase alpha for a female infant patient with hypophosphatasia who lacked apparent severe clinical symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>The patient exhibited low serum alkaline phosphatase (60 U\/L; age-matched reference range, 520\u20131,580) in a routine laboratory test at birth. Further examinations revealed skeletal demineralization and rachitic changes, as well as elevated levels of serum calcium (2.80 mmol\/L; reference range, 2.25\u20132.75 mmol\/L) and ionic phosphate (3.17 mmol\/L; reference range, 1.62\u20132.48 mmol\/L), which are typical features in patients with hypophosphatasia. Sequencing analysis of the tissue-nonspecific alkaline phosphatase (<jats:italic>TNSALP<\/jats:italic>) gene identified two pathogenic mutations: c.406C&amp;gt;T, p.Arg136Cys and c.979T&amp;gt;C, p.Phe327Leu. Thus, the patient was diagnosed with hypophosphatasia. At the age of 37 days, she began enzyme replacement therapy using asfotase alpha at the standard dose of 6 mg\/kg\/week. Initial therapy from the age of 37 days to the age of 58 days substantially improved rickets signs in the patient; it also provided immediate normalization of serum calcium and ionic phosphate levels. However, serum ionic phosphate returned to a high level (2.72 mmol\/L), which was presumed to be a side effect of asfotase alpha. Thus, the patient\u2019s asfotase alfa treatment was reduced to 2 mg\/kg\/week, which allowed her to maintain normal or near normal skeletal features thereafter, along with lowered serum ionic phosphate levels. Because the patient exhibited slight distal metaphyseal demineralization in the knee at the age of 2 years and 6 months, her asfotase alfa treatment was increased to 2.4 mg\/kg\/week. No signs of deterioration in bone mineralization were observed thereafter. At the age of 3 years, the patient\u2019s motor and psychological development both appeared normal, compared with children of similar age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is the first report in which reduced doses of asfotase alfa were administered to an infant patient with hypophosphatasia who lacked apparent severe clinical symptoms. The results demonstrate the potential feasibility of a tailored therapeutic option based on clinical severity in patients with hypophosphatasia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2020.590455","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T17:15:58Z","timestamp":1608311758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Efficacy of Reduced Doses of Asfotase Alfa Replacement Therapy in an Infant With Hypophosphatasia Who Lacked Severe Clinical Symptoms"],"prefix":"10.3389","volume":"11","author":[{"given":"Yasuko","family":"Fujisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Kitaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/212901a0","article-title":"Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(65)91422-4","article-title":"Excretion of inorganic pyrophosphate in hypophosphatasia","volume":"2","author":"Russell","year":"1965","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112031","article-title":"Markedly increased circulating pyridoxal-5\u2019-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism","volume":"76","author":"Whyte","year":"1985","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.01.020","article-title":"Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene","volume":"40","author":"Baumgartner-Sigl","year":"2007","journal-title":"Bone"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2013_224","article-title":"Outcome of perinatal hypophosphatasia in Manitoba Mennonites: a retrospective cohort analysis","volume":"11","author":"Leung","year":"2013","journal-title":"JIMD Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cen.13343","article-title":"Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: results from a Japanese clinical trial","volume":"87","author":"Kitaoka","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13023-018-0866-7","article-title":"Childhood hypophosphatasia: to treat or not to treat","volume":"13","author":"Rush","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins","volume":"4","author":"Payne","year":"1973","journal-title":"Br Med J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2019.01.049","article-title":"Natural history of perinatal and infantile hypophosphatasia: a retrospective study","volume":"209","author":"Whyte","year":"2019","journal-title":"J Pediatr"},{"key":"B15","unstructured":"The Tissue Nonspecific Alkaline Phosphatase Gene Mutations Database\n            MornetE"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J Trop Pediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3377","article-title":"Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: the Radiographic Global Impression of Change scale","volume":"33","author":"Whyte","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5719761","article-title":"Brief clinical report: hypophosphatasia-diagnostic considerations and treatment outcomes in an infant","volume":"2018","author":"Duffus","year":"2018","journal-title":"Case Rep Pediatr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","article-title":"Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa","volume":"122","author":"Kishnani","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1297\/cpe.29.9","article-title":"Clinical Practice Guidelines for Hypophosphatasia","volume":"29","author":"Michigami","year":"2020","journal-title":"Clin Pediatr Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00626-w","article-title":"Hypophosphatasia in Japan: ALPL mutation analysis in 98 unrelated patients","volume":"106","author":"Michigami","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0222931","DOI":"10.1371\/journal.pone.0222931","article-title":"Japanese nationwide survey of hypophosphatasia reveals prominent differences in genetic and dental findings between odonto and non-odonto types","volume":"14","author":"Okawa","year":"2019","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1612-9","article-title":"Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia","volume":"164","author":"Michigami","year":"2005","journal-title":"Eur J Pediatr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.11.003","article-title":"Hypophosphatasia","volume":"22","author":"Mornet","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4087-z","article-title":"Clinical, radiographic and biochemical characteristics of adult hypophosphatasia","volume":"28","author":"Schmidt","year":"2017","journal-title":"Osteoporos Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12887-019-1478-7","article-title":"Lethal perinatal hypophosphatasia caused by a novel compound heterozygous mutation: a case report","volume":"19","author":"Yu","year":"2019","journal-title":"BMC Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","article-title":"Alkaline Phosphatase and Hypophosphatasia","volume":"98","author":"Millan","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115300","article-title":"Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia","volume":"134","author":"Whyte","year":"2020","journal-title":"Bone"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000222","article-title":"A two-year follow-up of asfotase alfa replacement in a patient with hypophosphatasia: clinical, biochemical, and radiological evaluation","volume":"64","author":"Reis","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02335","article-title":"Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study","volume":"104","author":"Hofmann","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.590455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T17:16:03Z","timestamp":1608311763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.590455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":31,"alternative-id":["10.3389\/fendo.2020.590455"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.590455","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"article-number":"590455"}}